ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2015.2441 ETM-0-0-2441 Articles Association between serum leptin levels and peritoneal dialysis: A meta-analysis JIANGSHAN SONGKAI FENGSHENG SHIYONG-BIN Department of Nephrology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China Correspondence to: Dr Yong-Bin Shi, Department of Nephrology, The Second Affiliated Hospital of Soochow University, 1,055 Sanxiang Road, Suzhou, Jiangsu 215000, P.R. China, E-mail: su2h_syb@126.com 07 2015 22 04 2015 10 1 300 308 18062014 13022015 Copyright © 2015, Spandidos Publications 2015

There is limited information available with regard to the association between serum leptin levels, or other adipokines, and serum lipid levels and insulin sensitivity in patients undergoing peritoneal dialysis (PD). Thus, the aim of the present study was to perform a meta-analysis investigating this association. Potential relevant studies were identified through searching the following databases: MEDLINE, Science Citation Index, Cochrane Library, PubMed, Embase, CINAHL, Chinese Biomedical, Chinese Journal Full-Text and Weipu Journal. Statistical analyses were calculated using version 12.0 STATA software. In total, 21 case-control studies comprising 1,187 subjects (574 patients and 613 controls) were collected for the meta-analysis. The results identified a statistically significant difference in the serum levels of leptin when comparing the PD patients with the healthy controls [controls vs. cases, standardized mean difference (SMD), 2.09; 95% confidence interval (CI), 1.58–2.59; P<0.001]. Furthermore, ethnicity-subgroup analysis indicated that the PD patients of Asian and Caucasian populations were associated with increased serum levels of leptin (Asian population, SMD, 2.05; 95% CI, 1.48–2.62; P<0.001; Caucasian population, SMD, 2.19; 95% CI, 1.19–3.18; P<0.001). Therefore, serum leptin levels may be used as a prognostic marker for PD.

 leptin serum peritoneal dialysis meta-analysis Introduction

Peritoneal dialysis (PD) is an effective and secure treatment method for patients with short-term (3–5 years) chronic kidney disease (CKD), and has been accepted as a form of renal replacement therapy (RRT) for end-stage renal disease (ESRD) patients (1). There are two forms of PD, consisting of automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD). Certain studies have shown that APD has a lower mortality risk compared with CAPD, with a mortality rate of 40% in patients undergoing APD and a rate of 60% in patients undergoing CAPD (2,3). In 2008, an estimated 196,000 patients were undergoing PD worldwide, which represents 11% of the total dialysis population (4). In the United States, ~368,000 patients underwent dialysis treatment in 2007, with only a 7.2% PD prevalence (5). However, the number of patients undergoing treatment with PD appears to be increasing worldwide, with 41% of patients treated with PD in developed countries and 59% of patients treated with PD in developing countries (4). PD, hemodialysis and kidney transplantation are the three major RRT modalities. In Hong Kong, PD is the first choice RRT for all ESRD patients (6,7). Due to the low cost, improved quality of life and excellent comparable survival rates, the use of PD has increased widely, and the treatment method has become an essential RRT for patients with ESRD (8). As an important risk factor contributing to diabetic foot ulceration, CKD, particularly with the enrollment of ESRD, has resulted in ~200,000 patients receiving PD therapy worldwide, which is increasing by >6% per annum (9,10). These data indicate that the increasingly wide application of PD is playing a critical role in the treatment of ESRD patients (11). Furthermore, a previous study demonstrated that ESRD is associated with the endocrine function of adipose tissue, and high levels of leptin and adiponectin have been reported in patients with ESRD (12).

Leptin is a protein product of the obese gene and one of the adipocytokines primarily secreted by white adipocytes (13). The protein is formed of 167 amino acids and has a molecular weight of 16 kDa (13). Leptin, via afferent signaling in the hypothalamus, is known to be involved in regulating the fat stored in the body and maintaining energy homeostasis, with the means of exerting influences on the sensation of hunger, energy intake and energy expenditure (14). Through increasing the utilization of glucose and the metabolism of oxidative glucose in adipocytes, insulin indirectly promotes leptin production (15). Serum concentrations of leptin are reported to be increased in obese individuals, due to a reduced ability to detect satiety, and have been associated with the fat content of the body (16). Serum leptin levels are also known to be higher in patients who are undergoing PD, such as patients with hemolytic uremic syndrome, when compared with individuals with normal renal function. This observation may be caused by the filtering of leptin at the glomerulus without obstruction and the degradation of the protein in the renal tubules, as a result of the impaired clearance by the kidney (17,18). In addition, malnutrition is a dominant characteristic of uremic syndrome, and nutritional indicators, including the body mass index (BMI), the distribution of body fat and the plasma concentration of albumin, are known to be associated with the development of renal failure (19,20). Inversely, decreased levels of total protein and albumin in renal failure patients may reflect the catabolism of protein, and hypoalbuminemia is strongly associated with malnutrition (21). Overexpression of serum leptin is hypothesized to be an independent risk factor for PD, due to the close association between peritonitis and the malnutrition resulting from chronic inflammation. PD may in certain cases be attributed to a higher expression of leptin clearance, as the plasma concentrations of leptin in the patients increase correspondingly (20). Previous studies have agreed with the hypothesis that hyperleptinemia is a leading cause of protein malnutrition, and that PD may be responsible for the higher levels of leptin (22,23); however, alternative studies have reported that high serum concentrations of leptin may not be present in PD patients (20,24). As a result, the aim of the present study was to perform a meta-analysis investigating the correlation between high plasma levels of leptin and PD.

 Materials and methods <sec> <title>Search strategy

Potentially relevant studies were identified through a comprehensive literature search without language restriction, which covered the following computerized bibliographic databases: MEDLINE (1966–2014), Science Citation Index (1945–2014), Cochrane Library (Oxford, UK, Issue 12, 2014), PubMed (1966–2014), Embase (1974–2014) and CINAHL (1982–2014). In addition, the following three Chinese databases were included in the search to identify Chinese-language articles: Chinese Biomedical (1978–2014), Chinese Journal Full-Text (1980–2014) and Weipu Journal (1989–2014). The following medical subject headings and free language terms were used in conjunction with a highly sensitive search strategy. The search terms were as follows: ʻPDʼ or ʻPeritoneal Dialysisʼ, ʻContinuous Ambulatory PDʼ or ʻCAPDʼ, ʻContinuous Cycling PDʼ or ʻCCPDʼ or ʻperitoneum dialysisʼ, and ʻLeptinʼ, ʻObese Proteinʼ, ʻObese Gene Productʼ, ʻOb Gene Productʼ or ʻOb Proteinʼ. Additionally, reference lists of relevant studies selected from the electronic debates were searched manually to identify additional studies.

 Inclusion and exclusion criteria

To be included in the systematic review, retrieved studies were assessed for their suitability in meeting the following criteria: i) Search results were conducted within a human population and published in a peer-reviewed journal; ii) only case-control studies examining the association between serum leptin levels and patients undergoing PD were incorporated into the meta-analysis; iii) all the patients satisfied the guideline criteria for PD (25); iv) articles were required to present original data and supply sufficient information with regard to the serum leptin levels; and v) when studies provided overlapping data, the study that had the largest sample number was selected. The major exclusion criteria in this systematic review were as follows: i) Articles that did not satisfy the current inclusion criteria; ii) certain publication types, including letters, abstracts, reviews, meta-analyses and proceedings; iii) unpublished sources of data; iv) duplication publications or studies without extractable, numerical data; and v) subgroup analysis of the included trials. With the application of these inclusion criteria, the title and abstract of all the articles were evaluated on relevance. From the selected articles, the full texts were reviewed, followed by a decision on their eligibility for inclusion.

 Study quality and data extraction

In order to ensure consistency in reviewing and reporting the results, two reviewers independently assessed the methodological quality of the included trials using the Newcastle-Ottawa Scale (NOS) criteria with regard to study design, content and ease-of-use in the explanation of results or the meta-analysis for assessing the quality (26). Three broad perspectives were judged, including subject selection (0–4), subject comparability (0–2) and clinical outcome (0–3). The subject selection criteria included four sub-criteria: i) Adequacy of case definition; ii) representativeness of the cases; iii) selection of control; and iv) definition of controls. Subject comparability comprised a single critera; the comparability of cases and controls on the basis of the design or analysis. Clinical outcome consisted of three sub-criteria; the ascertainment of clinical outcome, a consistent method of ascertainment for cases and controls and non-response rate (http://www.biomedcentral.com/1471-2288/14/45). The NOS scores ranged between 0 and 9; a study was classified as good quality for the evidence with a score of ≥7.

Each of the two reviewers assessed the studies independently based on the aforementioned inclusion/exclusion criteria. A standardized data form in duplicate was used to collect the following descriptive information of the included studies: Surname and initials of the first author, the year of publication or submission, journal, source country, racial descent of the study population, language of publication, study design, number of cases and controls, demographic variables of the subjects, detection method of the serum leptin levels and baseline leptin levels in the cases and the controls. Disagreement on the inclusion of a single study was settled by discussion, or a third investigator was consulted.

 Statistical analysis

The effect size was represented by the mean ± standard difference, which was used to calculate the serum leptin levels in patients undergoing PD and healthy controls. A confidential interval of 95% (95%CI) was calculated for all mean values, using the Z-test. In addition, a test for the heterogeneity between the included trials for each comparison was performed using the Cochran's Q test and I2 tests (27). If the Q test showed evidence of a P-value of <0.05 or if the I2 test exhibited a value of >50%, which indicated maximal heterogeneity among the included studies, a meta-regression analysis with a random-effects model was conducted to investigate the sources of heterogeneity, while in other cases, the SMD values were pooled in accordance with the fixed-effects model (28,29). When substantial heterogeneity was identified, the differences in the leptin levels (and 95% CI) were evaluated among subgroups for different explanatory variables. Additionally, in order to evaluate the impact of single studies on the overall estimate, a one-way sensitivity analysis was employed. Furthermore, Egger's linear regression test, with visual inspection of the funnel plot, was applied to detect the potential publication bias (30,31). Statistical analyses were conducted using STATA statistical software (version 12.0; Stata Corporation, College Station, TX, USA).

 Results <sec> <title>Description of the included studies

The combined electronic and manual search initially resulted in 133 potentially eligible articles. Following the identification of two duplicated studies, the retrieved studies (n=131) were screened by their title and abstract for relevance. Subsequently, 63 irrelevant articles were excluded. The remaining 68 articles that qualified for full-text reading were systematically reviewed. After reading the full text, 45 articles were deemed unsuitable and were therefore excluded. Thus, 23 articles were included in the qualitative analysis. However, an additional two studies were excluded due to lack of data integrity following a more careful assessment of the remaining articles. A flow diagram of the study selection progress and the main reasons for exclusion is shown in Fig. 1 Finally, 21 case-control studies, comprising 574 patients that had undergone PD and 613 controls, were incorporated into the current meta-analysis (15,20,22–24,32–47). All the eligible studies had been published between 1997 and 2014 (Fig. 2), and all the enrolled papers exhibited moderate to high quality.

With regard to the demographic variables of the 21 included studies, 13 studies were performed with an Asian study population, while the remaining eight studies included a Caucasian study population. With regard to the methods used to detect the leptin levels, 11 studies utilized a radioimmunoassay (RIA), while the remaining 10 studies performed an enzyme-linked immunosorbent assay (ELISA). Table I presents the baseline characteristics of the study populations and the characteristics of the included studies.

 Quantitative data synthesis

In the meta-analysis, the serum leptin levels in the patients receiving PD and the controls were analyzed using a random effects model due to the evidence of heterogeneity (controls vs. cases, I2=91.8%, P<0.001). Additionally, since a significant heterogeneity was shown to exist, the studies were stratified by ethnicity (Asian population subgroup, I2=89.9%, P<0.001; Caucasian population subgroup, I2=93.9%, P<0.001) and detection methods (ELISA subgroup, I2=90.9%, P<0.001; RIA subgroup, I2=92.3%, P<0.001). Results from the meta-analysis revealed a statistically significant difference in the serum levels of leptin between the PD patients and the healthy controls. Higher serum concentrations of leptin were observed in the PD patients when compared with the controls, according to the random effects pooled SMD in the 21 included studies (controls vs. cases, SMD, 2.09; 95% CI, 1.58–2.59; P<0.001; Fig. 3).

With regard to the ethnicity-stratified subgroup analysis, the results from the meta-analysis revealed that the PD patients were associated with increased serum leptin levels in contrast to the healthy controls in the Asian population subgroup (controls vs. cases, SMD, 2.05; 95% CI, 1.48–2.62; P<0.001). Additionally, higher serum leptin levels were observed more frequently in the PD patients in the Caucasian population subgroup (controls vs. cases, SMD, 2.19; 95% CI, 1.19–3.18; P<0.001). Furthermore, in the method-stratified subgroup analysis, the PD patients were found to have higher serum leptin levels in the ELISA subgroup (controls vs. cases, SMD, 1.86; 95% CI, 1.19–2.52; P<0.001), and a similar correlation was also observed in the RIA subgroup (controls vs. cases, SMD, 2.29; 95% CI, 1.53–3.06; P<0.001; Fig. 4).

Further sensitivity analyses were conducted to determine whether the review conclusions were affected by the selection of a single study, and the findings indicated that no single study had an effect on the pooled SMD values in the current meta-analysis (Fig. 5). Finally, Egger's regression analysis displays the asymmetrical distribution of the funnel plot, which indicates publication biases in the differences in serum leptin levels between patients undergoing PD and controls (t=4.87; P<0.001) in the systematic reviews (Fig. 6).

 Discussion

The aim of the present meta-analysis was to investigate the association between high serum levels of leptin and PD. The results of the meta-analysis demonstrated that high leptin levels were closely associated with PD, indicating that PD therapy may not be an effective therapy for the clearance of leptin. As the first adipocyte-derived hormone, leptin is a 16 kDa peptide hormone with 146 amino acids, which is formed by cleaving a signal peptide of 21 amino acids from its prototype in the blood (48). Leptin plays a role in the central nervous system through hypothalamic pathways, with its main function to cause a decrease in food intake and an increase in the metabolic rate, promoting weight loss and the regulation of the energy balance (39). In addition to the effect on the central nervous system, leptin is also able to inhibit the secretion of insulin, increase natriuresis, diuresis and angiogenesis, and promote the calcification of vessels and increase oxidative stress (49). Thus, leptin is associated with a number of diseases, such as coronary artery calcification, vascular dysfunction, hypertension and kidney diseases (50). The metabolic pathway of leptin is through glomerulus filtration, followed by degradation within the renal tubules; thus, a high serum level of leptin is often observed in kidney disease patients (51). Elevated serum leptin levels may cause weight loss, malnutrition and anorexia, which can deteriorate the symptoms of kidney disease patients and are detrimental for the long-term survival of patients (36,52). PD, as a first-choice RRT, uses the peritoneum as a dialysis membrane, and is a safe and gentle method to correct metabolic and electrolytic disturbances generated in kidney diseases, including the clearance of leptin (53). However, PD is only partially able to clear leptin, and the clearance volume in PD and the high level of leptin have been found to be positively associated (54). In PD patients, the filtration rate of the glomerulus is decreased due to renal impairment; thus, the renal clearance of leptin is decreased, which leads to high serum leptin levels (55). Furthermore, the increased glucose load results in chronic hyperinsulinemia, which subsequently stimulates the insulin level and regulates the gene expression of leptin, ultimately causing high leptin serum levels (15). From these observations, it was hypothesized that high leptin levels in kidney disease patients may deteriorate the symptoms of the patients by causing malnutrition and anorexia. In addition, PD was hypothesized to be closely associated with the high leptin level, through the insufficient physical clearance, renal impairment and the increase in the indirect glucose load, which subsequently regulated the increased expression of leptin. Malyszko et al also observed increased levels of leptin in PD patients, which represented a connection between inflammation and adipocytokines, and the authors concluded that the dialysis time and adequacy may affect the clearance of leptin in patients undergoing dialysis (35).

Since a number of factors may influence the association between high serum levels of leptin and PD, a stratified analysis based on the ethnicity of the study population and the leptin detection method was established. The ethnicity subgroup analysis revealed a significant association between the leptin serum level increase and PD therapy in Asian and Caucasian populations, which may demonstrate that no racial difference exists between the high leptin level and PD. Therefore, the results of the present study are in accordance with previous studies that demonstrated a close connection between PD therapy and an increase in serum leptin levels (19,22,43). These observations indicate that PD therapy may contribute potential damage to renal function and subsequently have an influence on the clearance of leptin; thus, additional measures should be undertaken to reduce the leptin level in PD patients and improve the treatment of kidney disease.

However, there were a number of limitations in the current meta-analysis that should be taken into consideration. Firstly, the existence of heterogeneity, since the groups were not homogenous with respect to age, BMI, smoking status, ethnicity and serum level detection methods, and the insulin sensitivity of the patients was not further investigated. Notably, certain publication convention may be acknowledged that positive results tend to be more acceptable by journals, while negative researches are often easy to be rejected or not submitted for review. Thus, the lack of negative results may restrict a broader experiment and constrict the findings of the present study to a large extent. Furthermore, language introduces bias and those publications prone to be published in English language-based journals. Thirdly, although this study was based on relatively large sample size studies, a relatively small sample size may limit the detection of more subtle changes over time. In addition, regardless of the underlying degree of glucose tolerance, fasting or diet, significant circadian fluctuations in the serum leptin concentration may obscure a number of small, but significant changes, in the serum leptin level, which may be a source of potential bias for longitudinal observation. Therefore, all these factors may result in an inconsistent outcome.

In conclusion, the present study reported increased serum leptin concentrations in patients undergoing PD therapy, indicating that PD therapy may contribute potential damage to renal function and affect the clearance of leptin. These results highlight the importance of leptin as a potential determinant of weight loss, malnutrition and anorexia, particularly in patients undergoing PD therapy. However, further studies with larger sample sizes are required to confirm the clinical utility of serum leptin as an important biomarker for PD patients.

 References ChaudharyKKhannaRBiocompatible peritoneal dialysis solutions: do we have one?Clin J Am Soc Nephrol5723732201010.2215/CJN.0572080920093342 KatavetinPTheerasinYTreamtrakanponWTreatment failure in automated peritoneal dialysis and double-bag continuous ambulatory peritoneal dialysisNephrology (Carlton)18545548201310.1111/nep.1210723730742 Cortés-SanabriaLParedes-CeseñaCAHerrera-LlamasRMComparison of cost-utility between automated peritoneal dialysis and continuous ambulatory peritoneal dialysisArch Med Res44655661201310.1016/j.arcmed.2013.10.01724211750 JainAKBlakePCordyPGargAXGlobal trends in rates of peritoneal dialysisJ Am Soc Nephrol23533544201210.1681/ASN.201106060722302194 ChaudharyKSanghaHKhannaRPeritoneal dialysis first: rationaleClin J Am Soc Nephrol6447456201110.2215/CJN.0792091021115629 SakthongPKasemsupVHealth utility measured with EQ-5D in Thai patients undergoing peritoneal dialysisValue Health15(Suppl)S79S84201210.1016/j.jval.2011.11.00522265072 KwanBCChowKMMaTKAutomated peritoneal dialysis in Hong Kong: there are two distinct groups of patientsNephrology (Carlton)18356364201310.1111/nep.1204923469775 GuneyISolakYAtalayHComparison of effects of automated peritoneal dialysis and continuous ambulatory peritoneal dialysis on health-related quality of life, sleep quality and depressionHemodial Int14515522201010.1111/j.1542-4758.2010.00465.x20955286 JohnsonDWBrownFGClarkeMbalANZ Trial Investigators: Effects of biocompatible versus standard fluid on peritoneal dialysis outcomesJ Am Soc Nephrol2310971107201210.1681/ASN.201112120122440906 KaminskiMFrescosNTuckerSPrevalence of risk factors for foot ulceration in patients with end-stage renal disease on haemodialysisIntern Med J42e120e128201210.1111/j.1445-5994.2011.02605.x21999812 WeinhandlEDFoleyRNGilbertsonDTPropensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patientsJ Am Soc Nephrol21499506201010.1681/ASN.200906063520133483 KimSOhKHChinHJEffective removal of leptin via hemodiafiltration with on-line endogenous reinfusion therapyClin Nephrol72442448200910.5414/CNP7244219954721 MarwarhaGGhribiOLeptin signaling and Alzheimer's diseaseAm J Neurodegener Dis1245265201223383396 MutabarukaMSAouladAissa MDelalandreALocal leptin production in osteoarthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expressionArthritis Res Ther12R20201010.1186/ar292520141628 TaskapanMCTaskapanHSahinISerum leptin, resistin and lipid levels in patients with end stage renal failure with regard to dialysis modalityRen Fail29147154200710.1080/0886022060109582717365928 FangTCLeeCJWangCHFasting serum leptin level correlates with mid-arm fat area in peritoneal dialysis patientsTher Apher Dial14583588201010.1111/j.1744-9987.2010.00847.x21118367 BrileyLPSzczechLALeptin and renal diseaseSemin Dial195459200610.1111/j.1525-139X.2006.00119.x16423182 MakRHCheungWConeRDMarksDLLeptin and inflammation-associated cachexia in chronic kidney diseaseKidney Int69794797200610.1038/sj.ki.500018216518340 Pérez-FontánMCordidoFRodríguez-CarmonaAPlasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysisNephrol Dial Transplant1920952100200410.1093/ndt/gfh31315187192 KaynarKKuralBVUlusoySIs there any interaction of resistin and adiponectin levels with protein-energy wasting among patients with chronic kidney diseaseHemodial Int18153162201410.1111/hdi.1207223919731 HorwichTBKalantar-ZadehKMacLellanRWFonarowGCAlbumin levels predict survival in patients with systolic heart failureAm Heart J155883889200810.1016/j.ahj.2007.11.04318440336 HilkensMGNeteaMGVan der MeerJWKoolenMILeptin and proinflammatory cytokines in patients undergoing peritoneal dialysisEur J Clin Invest33525526author reply 527–528200310.1046/j.1365-2362.2003.01174.x12795651 HowardJKLordGMClutterbuckEJPlasma immunoreactive leptin concentration in end-stage renal diseaseClin Sci (Lond)9311912619979301426 ZhangLLiuJXuDMClearance effect of peritoneal dialysis on leptinJ Southeast Univ295395422010 TsubakiharaYNishiSAkibaT2008 Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney diseaseTher Apher Dial14240275201010.1111/j.1744-9987.2010.00836.x20609178 StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol25603605201010.1007/s10654-010-9491-z20652370 ZintzarasEIoannidisJPHEGESMA: genome search meta-analysis and heterogeneity testingBioinformatics2136723673200510.1093/bioinformatics/bti53615955784 ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol28123137200510.1002/gepi.2004815593093 HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med2115391558200210.1002/sim.118612111919 SongFGilbodySBias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysisBMJ31647119989492690 PetersJLSuttonAJJonesDRComparison of two methods to detect publication bias in meta-analysisJAMA295676680200610.1001/jama.295.6.67616467236 WrightMWoodrowGO'BrienSCholecystokinin and leptin: their influence upon the eating behaviour and nutrient intake of dialysis patientsNephrol Dial Transplant19133140200410.1093/ndt/gfg47114671048 VigniobleMBrichardSJadoulMGoffinESerum leptin concentration in peritoneal dialysis patients: determinants, longitudinal evolution and circadian rhythmActa Clin Belg56173179200110.1179/acb.2001.02711484514 TsujimotoYShojiTTabataTLeptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patientsAm J Kidney Dis34832838199910.1016/S0272-6386(99)70039-910561138 MalyszkoJMalyszkoJSMysliwiecMVisfatin and endothelial function in dialyzed patientsNephrology (Carlton)15190196201010.1111/j.1440-1797.2009.01180.x20470278 MałgorzewiczSLichodziejewska-NiemierkoMAleksandrowicz-WronaEAdipokines, endothelial dysfunction and nutritional status in peritoneal dialysis patientsScand J Urol Nephrol44445451201010.3109/00365599.2010.50419120624111 LandtMParvinCADagogo-JackSLeptin elimination in hyperleptinaemic peritoneal dialysis patientsNephrol Dial Transplant14732737199910.1093/ndt/14.3.73210193829 JohansenKLMulliganKTaiVSchambelanMLeptin, body composition and indices of malnutrition in patients on dialysisJ Am Soc Nephrol91080108419989621292 BuyanNBideciAOzkayaOLeptin and resistin levels and their relationships with glucose metabolism in children with chronic renal insufficiency and undergoing dialysisNephrology (Carlton)11192196200610.1111/j.1440-1797.2006.00570.x16756630 YangFFLinXWangJLuoZWEffect observation of peritoneal dialysis on clearance of hyperleptinemia and inflammatory factor in uremic patientsChongqing Yi Yao403435,372011(In Chinese) XuXDHuPWangNSThe relationship between leptin and nutrition status in patients with chronic renal failure undergoing different ways of blood purificationXuzhou Yi Ke Da Xue2885882008(In Chinese) WuRMaKWangJAnalysis of serum leptin and inflammatory cytokines in peritoneal dialysis clear uremic patientsChin and Foreign Health Abstract84684682011 WuJQZhouZSPanZXLiHZAn analysis for the relationship between leptin and the nutrition status in peritoneal dialysis patientsZhongguo Ji Ceng Yi Yao131851862006(In Chinese) WangZMWangQYuJSEffects of peritoneal dialysis on indexes in patients with chronic renal failureXian Dai Zhong Xi Yi Jie He Za Zhi191185118612262010(In Chinese) ZuoJZouJZFangYSerum leptin levels and malnutrition in chronic renal failureShanghai Yi Xue6796822002(In Chinese) MaYZhaoJSunXWSerum leptin levels and its clinical significance in patients with different stages of chronic renal failureZhong Guo Xian Dai Yi Yao Za Zhi1342452011(In Chinese) GuanXZhengHGAnalysis of leptin levels in peritoneal dialysis patients and its influencing factorsZhong Guo Shi Yong Nei Ke Za Zhi2619212006(In Chinese) AnWSSonYKKimSEAssociation of adiponectin and leptin with serum lipids and erythrocyte omega-3 and omega-6 fatty acids in dialysis patientsClin Nephrol75195203201110.5414/CNP7519521329629 HouNLuoJDLeptin and cardiovascular diseasesClin Exp Pharmacol Physiol38905913201110.1111/j.1440-1681.2011.05619.x21957899 DíezJJBossolaMFernández-ReyesMJRelationship between leptin and all-cause and cardiovascular mortality in chronic hemodialysis patientsNefrologia31206212201121461015 GolembiewskaESafranowKCiechanowskiKAdipokines and parameters of peritoneal membrane transport in newly started peritoneal dialysis patientsActa Biochim Pol60617621201324364044 BeberashviliISinuaniIAzarALongitudinal study of leptin levels in chronic hemodialysis patientsNutr J1068201110.1186/1475-2891-10-6821676262 PonceDCaramoriJTBarrettiPBalbiALPeritoneal dialysis in acute kidney injury: Brazilian experiencePerit Dial Int32242246201210.3747/pdi.2012.0008922641732 FontánMPRodríguez-CarmonaACordidoFGarcía-BuelaJHyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis and hemodialysis: A comparative analysisAm J Kidney Dis34824831199910.1016/S0272-6386(99)70038-710561137 TsaiJPTsaiCCLiuHMHyperleptinaemia positively correlated with metabolic syndrome in hemodialysis patientsEur J Intern Med22e105e109201110.1016/j.ejim.2011.02.01522075293

Flow chart showing the literature search and study selection procedure. In total, 21 case-control studies were included in the meta-analysis.

Distribution of topic-related literature in an electronic database over the last decade.

Forest plot showing the differences in the serum leptin levels between patients undergoing peritoneal dialysis and healthy controls. CI, confidence interval; SMD, standardized mean difference.

Subgroup analyses indicating the differences in the serum leptin levels between patients undergoing peritoneal dialysis and healthy controls. CI, confidence interval; SMD, standardized mean difference; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay.

Sensitivity analysis of the standardized mean difference coefficients of the differences in the serum leptin levels between patients undergoing peritoneal dialysis and healthy controls. CI, confidence interval.

Funnel plot showing the publication biases with regard to the differences in the serum leptin levels between patients undergoing peritoneal dialysis and healthy controls. SMD, standardized mean difference; SE, standard error.

Characteristics of the included studies focused on the serum levels of leptin.

Sample size (n) Gender, M/F (n) Mean age (years)
First author (reference) Year Ethnicity Case Control Case Control Case Control Method NOS score
Kaynar K (20) 2014 Asian 30 30 – – 39.1±13.4 33.4±9.4 ELISA 6
Yang FF (40) 2011 Asian 30 30 17/13 – 61.7±14.0 – RIA 6
Wu R (42) 2011 Asian 26 30 15±11 – 53.3±12.7 – ELISA 6
Ma Y (46) 2011 Asian 20 20 12±8 – 55.8±14.5 – RIA 6
Zhang L (24) 2010 Asian 20 13 11±9 6±7 58.8±11.4 57.8±12.7 RIA 6
Wang ZM (44) 2010 Asian 45 30 24±21 17±13 60.4±10.2 58.5±12.9 RIA 8
Malyszko J (35) 2010 Caucasian 40 22 – 11±9 52.3±12.5 56.0±14.8 RIA 7
Małgorzewicz S (36) 2010 Caucasian 30 23 12±18 8±15 57.3±16.6 63.3±7.8 ELISA 7
Xu XD (41) 2008 Asian 40 40 – – – – RIA 6
Taskapan MC (15) 2007 Asian 30 30 18±12 17±13 43.2±10.8 40.9±10.0 ELISA 7
Wu JQ (43) 2006 Asian 26 26 – – – – ELISA 6
Guan X (47) 2006 Asian 30 30 16±14 19±11 52.3±3.1 51.2±3.6 ELISA 7
Buyan N (39) 2006 Asian 24 23 – – 13 (7–18) 14 (4–18) RIA 6
Wright M (32) 2004 Caucasian 39 43 23±16 22±21 53 (23–75) 50 (36–73) ELISA 7
Hilkens MG (22) 2003 Caucasian 10 10 5±5 5±5 49 49 ELISA 6
Zuo J (45) 2002 Asian 9 13 8±1 8±5 61.0±12.0 52.0±6.0 ELISA 6
Vignioble M (33) 2001 Caucasian 23 35 10±13 16±19 – – RIA 6
Tsujimoto Y (34) 1999 Asian 46 67 28±18 37±30 50.0±1.6 50.6±1.0 ELISA 8
Landt M (37) 1999 Caucasian 28 28 14±14 14±14 54.5±17.7 36.8±8.0 RIA 6
Johansen KL (38) 1998 Caucasian 9 41 5±4 21±20 43.0±15.0 36.0±10.0 RIA 6
Howard JK (23) 1997 Caucasian 19 29 – – – – RIA 6

M, male; F, female; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; NOS, Newcastle-Ottawa Scale.